A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma

NCT00742560 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

101

Enrollment

INDUSTRY

Sponsor class

Conditions

Hematologic Cancer

Interventions

BIOLOGICAL: elotuzumab
DRUG: lenalidomide
DRUG: dexamethasone oral
DRUG: dexamethasone injection

Sponsor

AbbVie (prior sponsor, Abbott)

Collaborators

[object Object]